Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
PD-1
PD-L1
immunotherapy
renal cancer
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2019
2019
Historique:
received:
16
03
2019
accepted:
13
06
2019
entrez:
21
8
2019
pubmed:
21
8
2019
medline:
21
8
2019
Statut:
epublish
Résumé
The aim of this study was to perform a literature-based meta-analysis to assess the efficacy of the novel immune checkpoint inhibitors (ICIs) in first-line metastatic renal cell carcinoma (RCC), focusing on the predictive role of PD-L1 expression. The primary outcome was overall survival, and secondary outcomes were progression-free survival (PFS) and objective response. We planned a subgroup analysis for overall survival according to PD-L1 status. Five studies were included in the analysis for a total of 4063 cases. Overall survival was greater in PD-L1 positive tumours (HR = 0.49, 95% CI: 0.36-0.67; This study supports the efficacy of ICIs and, although a significant clinical benefit has been reported in PD-L1 negative patients, a greater efficacy of ICIs was observed in PD-L1 positive patients. More prospective randomized studies are needed to clarify the role of PDL-1 status in metastatic RCC treated with ICIs.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to perform a literature-based meta-analysis to assess the efficacy of the novel immune checkpoint inhibitors (ICIs) in first-line metastatic renal cell carcinoma (RCC), focusing on the predictive role of PD-L1 expression.
METHODS
METHODS
The primary outcome was overall survival, and secondary outcomes were progression-free survival (PFS) and objective response. We planned a subgroup analysis for overall survival according to PD-L1 status.
RESULTS
RESULTS
Five studies were included in the analysis for a total of 4063 cases. Overall survival was greater in PD-L1 positive tumours (HR = 0.49, 95% CI: 0.36-0.67;
CONCLUSIONS
CONCLUSIONS
This study supports the efficacy of ICIs and, although a significant clinical benefit has been reported in PD-L1 negative patients, a greater efficacy of ICIs was observed in PD-L1 positive patients. More prospective randomized studies are needed to clarify the role of PDL-1 status in metastatic RCC treated with ICIs.
Identifiants
pubmed: 31428205
doi: 10.1177/1758835919861905
pii: 10.1177_1758835919861905
pmc: PMC6683319
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835919861905Déclaration de conflit d'intérêts
Conflict of interest statement: Authors declare that no potential conflicts of interest exist (e.g. personal or financial relationships that could influence their actions or sources of funding) and disclose they have received no writing assistance for the manuscript.
Références
J Clin Oncol. 1999 Aug;17(8):2530-40
pubmed: 10561319
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Cancer. 2005 Nov 15;104(10):2084-91
pubmed: 16208700
Cancer Res. 2006 Apr 1;66(7):3381-5
pubmed: 16585157
Clin Cancer Res. 2007 Mar 15;13(6):1757-61
pubmed: 17363529
Cancer Immunol Res. 2015 Oct;3(10):1158-64
pubmed: 26014095
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Crit Rev Oncol Hematol. 2016 Apr;100:88-98
pubmed: 26895815
Medicine (Baltimore). 2017 May;96(18):e6369
pubmed: 28471952
J Natl Compr Canc Netw. 2017 Jun;15(6):804-834
pubmed: 28596261
Lancet Oncol. 2018 Apr;19(4):451-460
pubmed: 29530667
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
J Cancer Res Ther. 2018 Oct-Dec;14(6):1167-1175
pubmed: 30488824
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797